Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (June 2025)
11 slides from Canaquest Medical's investor presentation, Jun 25, 2025
Slide 1: Vision: To be the Global Leader in Next-Gen Epilepsy & Neurological Treatments
Vision: To be the Global Leader in Next-Gen Epilepsy & Neurological Treatments INVESTOR PRESENTATION SV June 25, 2025 A Clinical Stage/Life Sciences company www.canaquest.com
Slide 2: Problem
Problem | Refractory Epilepsy has an unmet need, & Neurological Conditions are on the rise ➢ ➢ ➢ ➢ ➢ Targeted Syndromes: - Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis Complex → Rare epilepsies with high unmet medical need Source: ¹WHO
Slide 3: Solution
Solution | Transforming Epilepsy & Neurological Treatment with CQ-001 ❖ ❖ ❖ ❖ ❖
Slide 4: Financials & Ask
Financials & Ask | Join the Mission: Redefine Epilepsy Care Funding Stage Amount Use of Funds Status US$350K soft-circled NDA, Dose Optimization, Seed Round US$1.5M Ontario Centre of Innovation IP Expansion - match pending US$1.15 remaining $10M soft-circled – VC Firm Clinical Trials, Manufacturing,
Slide 5: Product Differentiation
Product Differentiation | CQ-001: Safer, More Effective Option Drug Mechanism of Action Tolerability Efficacy Cognition Epidiolex Cannabidiol only Moderate Effective Limited Cannabidiol + EPA/DHA CQ-001 High ↑ 35% vs Cannabidiol Improves Function = PPAR activation Key Advantages of CQ-001: ❖ Improve
Slide 6: Multi-Indication Blockbuster Potential
Multi-Indication Blockbuster Potential | Right Science. Right Team. Right Timing. ❖ Five indications over 50 years ❖ Epilepsy, Depression, PTSD, anxiety, TBI ❖ IP strategy and platform formulation ❖ Pathway to orphan drug status - epilepsy ❖ Scalable platform across CNS disorders “After examining Ca
Slide 7: Market Opportunity
Market Opportunity | A $70B+ Global Market in Refractory Epilepsy Alone ❖ 17.5M refractory epilepsy patients globally ❖ $2.8B+ serviceable addressable market (US & Canada), ~70,000 patients ❖ Best in class advantage in rare syndromes ❖ Safer alternative to Epidiolex ❖ Platform for new indications
Slide 8: Business Model
Business Model | Strategic Path ❖ Orphan Drug pathway → fast track approval ❖ Physician off-labeling - supports early adoption ❖ Partnering post-Phase IIb - large pharma ❖ Revenue from out-licensing across CNS disorders ❖ Platform for veterinary opportunities
Slide 9: Team
Team | Scientific Team Driving the Next Frontier in Neurological Care Dr. Jordyn Stuart, Ph.D., BS, BS (Acting CSO) – 6 years with GW Pharma, Medical Affairs & launch of Epidiolex® - CNS-targeted formulations Dr. Hunter Land, Ph.D., MS (Chief Scientific Advisor) – Led development of Epidiolex at GW
Slide 10: Validation & Exit Potential
Validation & Exit Potential | CQ-001 Benchmarking & Opportunity ❖ Guided by GW Pharma veterans and experts¹ ❖ $2M raised from angel investors ❖ Strong preclinical trial data ❖ Safer, more effective than competitors ❖ Positioning for Nasdaq or pharma acquisition² 1) Industry Experts: Ontario Brain In
Slide 11: Partnerships & Collaborations
Partnerships & Collaborations | Science, Clinical trial expertise, Team (proven success) Contact: Paul Ramsay, CEO 416-704-3040 | paul@canaquest.com www.canaquest.com Government Clinical Trial Mentorship & Pre-clinical Trials Grants Expertise expert resources Pre-clinical MES Government Clinical Stu
CanaQuest Medical — Investor Presentation (June 2025) on 6ix